Prevention and management of antineoplastic-induced hypersensitivity reactions
- PMID: 11676304
- DOI: 10.2165/00002018-200124100-00005
Prevention and management of antineoplastic-induced hypersensitivity reactions
Abstract
Acute hypersensitivity reactions (HSRs) are an unpredictable and potentially catastrophic complication of treatment with chemotherapeutic agents. Reactions may affect any organ system in the body and range widely in severity from mild pruritus to systemic anaphylaxis. Certain classes of chemotherapeutic agents, such as the taxanes, platinum compounds, asparaginases, and epipodophyllotoxins are commonly associated with HSRs. The clinical characteristics of these high risk agents with respect to HSRs are discussed in this review. Protocols to prevent or reduce the severity of these reactions have been developed, but despite these attempts, HSRs will still happen. Should a reaction occur, it is imperative that it be recognised quickly in order to minimise exposure to the inciting agent and implement appropriate therapeutic and supportive measures. When a patient becomes sensitised to a chemotherapeutic agent, avoidance of re-exposure is the mainstay of future prevention. For sensitised patients who have derived clinically meaningful benefit from a particular agent, however, continuation of treatment with the agent is desirable. Options may include attempting a trial of desensitisation or treatment with a related compound. Virtually all patients demonstrating HSRs to paclitaxel and docetaxel are able to successfully tolerate re-treatment following discontinuation and administration of diphenhydramine and hydrocortisone. Re-treatment has generally been less successful with platinum compounds. with recurrent HSRs occurring in up to 50% of patients following desensitisation protocols. Patients sensitised to asparaginase are often able to tolerate the alternative preparations, Erwinia carotovora asparaginase or polyethylene glycol-modified Escherichia coli asparaginase. There is very little experience with re-treatment following sensitisation to the epipodophyllotoxins. As re-treatment may have serious consequences, careful consideration of the risks and benefits of these strategies is imperative when deciding among these options.
Similar articles
-
Incidence, clinical features and management of hypersensitivity reactions to chemotherapeutic drugs in children with cancer.Eur J Clin Pharmacol. 2013 Oct;69(10):1739-46. doi: 10.1007/s00228-013-1546-0. Epub 2013 Jun 14. Eur J Clin Pharmacol. 2013. PMID: 23765411 Review.
-
Docetaxel as an alternative to paclitaxel after acute hypersensitivity reactions.Ann Pharmacother. 2000 Nov;34(11):1332-5. doi: 10.1345/aph.19383. Ann Pharmacother. 2000. PMID: 11098349 Review.
-
Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.Future Oncol. 2022 Mar;18(10):1285-1299. doi: 10.2217/fon-2021-1288. Epub 2022 Feb 2. Future Oncol. 2022. PMID: 35107320 Review.
-
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.Ann Allergy Asthma Immunol. 2009 Mar;102(3):179-87; quiz 187-9, 222. doi: 10.1016/S1081-1206(10)60078-6. Ann Allergy Asthma Immunol. 2009. PMID: 19354063 Review.
-
Review of hypersensitivity reactions to antineoplastic agents.Farm Hosp. 2012 May-Jun;36(3):148-58. doi: 10.1016/j.farma.2011.02.004. Epub 2012 Apr 5. Farm Hosp. 2012. PMID: 22484106 Review. English, Spanish.
Cited by
-
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era.Cells. 2022 Feb 22;11(5):770. doi: 10.3390/cells11050770. Cells. 2022. PMID: 35269392 Free PMC article. Review.
-
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.Support Care Cancer. 2012 Sep;20(9):1991-7. doi: 10.1007/s00520-011-1303-9. Epub 2011 Nov 17. Support Care Cancer. 2012. PMID: 22089428 Free PMC article.
-
Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients.Oncologist. 2014 Aug;19(8):823-8. doi: 10.1634/theoncologist.2013-0470. Epub 2014 Jul 25. Oncologist. 2014. PMID: 25063226 Free PMC article.
-
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer.Oncologist. 2021 Nov;26(11):927-933. doi: 10.1002/onco.13960. Epub 2021 Sep 24. Oncologist. 2021. PMID: 34472667 Free PMC article.
-
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.Drugs. 2016 May;76(8):853-67. doi: 10.1007/s40265-016-0573-4. Drugs. 2016. PMID: 27113582 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials